Mode
Text Size
Log in / Sign up
Phase 2 N=269 Randomized Quadruple-blind Treatment

A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine

Pain

Enrolled (actual)
269
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6) — 4.37; 20.75; 8.95; 20.56 units on a scale — p=<0.001

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
JNJ-10450232 / Not yet marketed (Drug); acetaminophen / Tylenol (Drug)
Age
Adult · 18+ yrs
Sex
Male
Sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Primary completion
Apr 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6)
4.37; 20.75; 8.95; 20.56 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 15 Minutes Post Dose
0.13; 0.25; 0.06; 0.21 0.448
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 30 Minutes Post Dose
0.25; 1.59; 0.46; 0.71 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 45 Minutes Post Dose
0.28; 3.22; 0.91; 1.51 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 1 Hour Post Dose
0.25; 3.98; 1.03; 2.19 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 1.5 Hours Post Dose
0.37; 4.35; 1.23; 2.85 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 2 Hours Post Dose
0.41; 4.20; 1.43; 3.48 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 3 Hours Post Dose
0.71; 3.84; 1.69; 3.86 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 4 Hours Post Dose
0.91; 3.78; 1.79; 4.17 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 5 Hours Post Dose
1.01; 3.56; 1.82; 4.14 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 6 Hours Post Dose
1.12; 3.04; 1.69; 4.07 <0.001 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 7 Hours Post Dose
1.13; 2.38; 1.66; 3.94 0.018 sig
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 8 Hours Post Dose
1.15; 1.99; 1.51; 4.00 0.102
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 9 Hours Post Dose
1.19; 1.69; 1.73; 3.91 0.338
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 10 Hours Post Dose
1.08; 1.60; 1.57; 3.87 0.306
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 11 Hours Post Dose
1.03; 1.58; 1.57; 3.70 0.279
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 12 Hours Post Dose
1.08; 1.57; 1.39; 3.61 0.329
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 16 Hours Post Dose
0.93; 1.37; 1.08; 3.43 0.380
SECONDARY
Pain Intensity Difference From Baseline (PID) Scores at 24 Hours Post Dose
1.15; 1.41; 1.29; 3.47 0.640
SECONDARY
Pain Relief (PAR) Scores at 15 Minutes Post Dose
0.27; 0.52; 0.33; 0.38 0.117
SECONDARY
Pain Relief (PAR) Scores at 30 Minutes Post Dose
0.60; 2.38; 0.90; 1.03 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 45 Minutes Post Dose
0.64; 4.42; 1.52; 2.11 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 1 Hour Post Dose
0.84; 5.18; 1.68; 3.09 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 1.5 Hours Post Dose
1.01; 5.88; 2.13; 3.97 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 2 Hours Post Dose
1.17; 5.88; 2.53; 4.90 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 3 Hours Post Dose
1.59; 5.39; 2.90; 5.40 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 4 Hours Post Dose
1.92; 5.31; 2.99; 5.83 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 5 Hours Post Dose
2.17; 5.00; 3.05; 5.77 <0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 6 Hours Post Dose
2.32; 4.42; 2.92; 5.68 0.001 sig
SECONDARY
Pain Relief (PAR) Scores at 7 Hours Post Dose
2.41; 3.62; 2.80; 5.57 0.067
SECONDARY
Pain Relief (PAR) Scores at 8 Hours Post Dose
2.41; 3.10; 2.63; 5.62 0.281
SECONDARY
Pain Relief (PAR) Scores at 9 Hours Post Dose
2.46; 2.73; 2.98; 5.50 0.674
SECONDARY
Pain Relief (PAR) Scores at 10 Hours Post Dose
2.28; 2.67; 2.81; 5.40 0.541
SECONDARY
Pain Relief (PAR) Scores at 11 Hours Post Dose
2.26; 2.63; 2.75; 5.25 0.573
SECONDARY
Pain Relief (PAR) Scores at 12 Hours Post Dose
2.34; 2.57; 2.53; 5.16 0.720
SECONDARY
Pain Relief (PAR) Scores at 16 Hours Post Dose
2.09; 2.23; 2.07; 4.96 0.821
SECONDARY
Pain Relief (PAR) Scores at 24 Hours Post Dose
2.44; 2.20; 2.33; 4.96 0.726
SECONDARY
Duration of Pain Relief After Dosing (Time to Rescue Medication)
109.0; 468.5; 129.0; NA 0.042 sig
SECONDARY
Subject Global Evaluation
62.7; 12.1; 55.1; 28.8; 14.9; 9.1 <0.001 sig

Summary

To assess the safety and effectiveness one dose of a new pain reliever medicine (JNJ-10450232 at either the 250 or 1000 mg strength) compared with placebo (sugar pill) or acetaminophen 1000 mg after surgical removal of third molars. The primary endpoint will evaluate pain relief effectiveness up to 6 hours after administration of the study drug.

Eligibility Criteria

Inclusion Criteria

  • Subjects aged 18-45 years
  • At least moderate dental pain assessed by a categorical scale pain intensity scale and a score of at least 5 on the 11-point (0-10) pain intensity numerical rating scale (PI-NRS) following surgical removal of three third-molars

Exclusion Criteria

  • Subjects who are not otherwise healthy
  • Test positive for the urine drug screen
  • Taking prohibited medications will not be allowed to participate in this study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02209181). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search